

consists merely of minor modifications or combination products, then the Task Force finds that much of the drug industry's research and development activities would appear to provide only minor contributions to medical progress. We likewise find that to the extent the industry directs a share of its research program to duplicative, noncontributory products, there is a waste of skilled research manpower and research facilities, a waste of clinical facilities needed to test the products, a further confusing proliferation of drug products which are promoted to physicians, and a further burden on the patient or taxpayer who, in the long run, must pay the costs.

Doesn't that strike you as a rather powerful indictment of the claim for the research by the independent industry?

Dr. SHAPIRO. It sounds very condemning.

Senator NELSON. That is the Task Force on Prescription Drugs composed of some very distinguished people. And this was issued on March 16, 1969.

Dr. SHAPIRO. I have no knowledge of this report, Mr. Chairman. It comes to my mind that possibly something that you read is a little out of context, and could be qualified. I do not know the report, I am very sorry.

Senator NELSON. This is the summary. And we would be entitled to go back, of course, and check the basis of their finding. But this is the finding that they made.

The thing that is disturbing to me, just as an observer, is how often it is asserted by representatives of the medical profession that no other industry in the United States invests more in research than the drug industry, which is the drug industry line, yet no one from the medical profession can ever explain how they came to that conclusion except that they are repeating what the pharmaceutical manufacturers said. Doesn't that bother you a little bit?

Dr. SHAPIRO. In that context, yes, Mr. Chairman. But having been out of school now for a little over 30 years, and watching the great innovations and the changed health care so completely, this came from some place.

Senator NELSON. The statement came from the pharmaceutical manufacturers.

Dr. SHAPIRO. I mean the progress that we have enjoyed. It did not just grow like Topsy, someone had to do it. We know it has been done.

Senator NELSON. No witness before the committee of which we have had a large number, has ever said that the industry has not made a valuable contribution in terms of research, and neither has any member of this committee said that. The committee is concerned about overdrawn claims. And when we have tried to chase this one down we never can get the answer. But the task force, which is a very distinguished group, makes a rather telling indictment of some of the kind of research and dissipation of money and presumed valuable research that the industry makes. That is my point.

Dr. SHAPIRO. We have no further information. As a matter of fact, you have more information than we have.

Mr. GORDON. Mr. Chairman, may I interrupt for a moment?

Dr. Goddard on April 6, 1966 at Boca Raton, Fla., at the annual meeting of the Pharmaceutical Manufacturers' Association said this:

Let me begin with investigational new drugs. I can say that I have been shocked at the quality of many submissions to our IND staff. The hand of the amateur is evident too often for my comfort. So-called research and so-called studies are